All In Biotech

Drug Trial Radar · NCT04253132

Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks

A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Tolfenamic Acid for the Treatment of Progressive Supranuclear Palsy

Last checked: Nov 19, 2026Latest source record: Feb 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

24

Planned (sponsor's estimate)

Start

Jan 1, 2021

Primary completion

Dec 31, 2022

Study completion Dec 31, 2022

Sponsor

Lead sponsor
NeuroTau, Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Cleveland Clinic
First posted
Feb 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 12-week study of oral tolfenamic acid vs. placebo in Progressive Supranuclear Palsy (PSP)

Conditions

  • Progressive Supranuclear Palsy

Interventions

  • Tolfenamic AcidDrug

    Tolfenamic acid is an NSAID closely resembling mefenamic and flufenamic acid.

  • PlacebosDrug

    oral placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerance of tolfenamic acid in individuals with PSPTime frame: 12-weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Lou Ruvo Center for Brain Health - Cleveland Clinic Nevada

    Las Vegas, Nevada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.